[Saint-Jude Medical tricuspid prosthesis. Long-term clinical, biological and echocardiographic assessment].
Twenty-four patients with a Saint-Jude Medical tricuspid valve prosthesis, aged 5 to 77 years, were studied. The etiology of the tricuspid lesion was rhumatic in 17 cases, infectious in 4 cases, and congenital in the other 3. Fourteen patient (58%) had undergone previous valve surgery, 7 of whom had undergone tricuspid valve replacement (TVR) by a bioprosthesis. Three patients were operated on for the third time. The TVR was isolated (4 cases) or associated with aortic valve replacement (3 cases), mitral valve replacement (8 cases), double aortic and mitral valve replacement (7 cases), repair of a ventricular septal defect (VSD) (1 case) and radical treatment of a Wolff-Parkinson-White syndrome (WPW) in 1 case. There were 3 early deaths (12.5%). Eighteen of the 21 survivors were followed up clinically, biologically (detection of hemolysis) and by Doppler echocardiography for an average period of 45 months (range 10 to 96 months). The clinical benefit was clear cut. No embolic complications were observed and there were no cases of hemolysis. The mean resting tricuspid pressure gradient was 3.57 +/- 2.36 mmHg. The Saint-Jude Medical prosthesis would therefore seem to be a good alternative to other mechanical valve prosthesis in the tricuspid position and without the risk of valve degeneration associated with bioprosthesis.